To the full analysis
SCHOTT Pharma AG & Co. KGaA stock: growth
1SXP.FSCHOTT Pharma AG & Co. KGaA reported $1.09B in revenue for fiscal 2025, up 3% on the prior year, up 11% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
11%
per year from 2020 to 2025, per share 11%
Earnings (Annual rate)
13.6%
per year from 2020 to 2025, per share 13.7%
Free cash flow (Annual rate)
13%
per year from 2020 to 2025, per share 13%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | |
|---|---|
| Revenue | 11.0% |
| Revenue per share | 11.0% |
| Earnings | 13.6% |
| Earnings per share | 13.7% |
| Free cash flow | 13.0% |
| Free cash flow per share | 13.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2020 | $647.38M | $85.86M | $21.15M |
| 2021 | $718.79M | $111.64M | $37.22M |
| 2022 | $909.91M | $138.93M | $32.62M |
| 2023 | $995.74M | $168.26M | $6.79M |
| 2024 | $1.06B | $165.87M | $88.68M |
| 2025 | $1.09B | $162.29M | $38.96M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Sep 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 13 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.